Result of AGM

RNS Number : 7885C
N4 Pharma PLC
19 June 2019
 

19 June 2019

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

Result of AGM

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, announces that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. All resolutions were passed on a show of hands.  The results of the proxy voting for the AGM is set out below.

 


Resolution

Total votes For1

% of votes cast2

Total Votes Against

% of votes cast2

Total Votes Cast3

% of issued share capital

Votes Withheld4

1

To receive the annual report and audited accounts for the year ended 31 December 2018

16,362,457

99.99

1,134

0.01

16,363,591

16.13

0

 

2

To re-elect Luke Cairns as a director of the Company

16,332,857

99.99

1,134

0.01

16,333,991

16.10

29,600

3

To elect John Chiplin as a Director of the Company

16,332,857

99.99

1,134

0.01

16,333,991

16.10

29,600

4

To elect Chris Britten as a Director of the Company

16,332,857

99.99

1,134

0.01

16,333,991

16.10

29,600

5

To re-appoint Saffery Champness LLP as auditor and authorise directors to determine their remuneration

16,334,857

99.85

25,000

0.15

16,359,857

16.12

3,734

6

Authority to allot shares

16,331,657

99.82

30,200

0.18

16,361,857

16.12

1.734

7

Authority to disapply pre-emption rights

16,330,457

99.97

5,334

0.03

16,335,791

16.10

27,800

 

Notes:

 

1.             Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution

2.             Percentage of votes cast excludes Votes Withheld

3.             Total Votes Cast do not include withheld votes

4.             Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution

 

Enquiries:

 

N4 Pharma Plc

Nigel Theobald, CEO

 

Via Scott PR

 

Allenby Capital Limited

James Reeve/Asha Chotai

 

Tel: +44(0)203 328 5656

Scott PR

Georgia Smith

 

 

Tel: +44(0)1477 539 539

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGBBGDLGUBBGCC

Companies

N4 Pharma (N4P)
UK 100

Latest directors dealings